Sanofi Strengthens Adult Vaccine Portfolio with $2.2B Dynavax Acquisition

Paris and Emeryville, CA, December 24, 2025 (Reuters) -- Sanofi announced it will acquire U.S.-based Dynavax Technologies in a deal valued at approximately $2.2 billion, adding an approved adult hepatitis B vaccine and a late-stage shingles candidate to its vaccines pipeline. The transaction, expected to close in Q1 2026, follows recent strategic moves by Sanofi to broaden growth beyond its blockbuster asthma treatment Dupixent, including acquisitions of Vicebio and BluePrint Medicines. Analysts note the deal also positions Sanofi to rebalance its vaccine exposure toward adults amid evolving U.S. policy debates around childhood immunization, with Dynavax shares jumping nearly 40% on the news.

Read full article here.